{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:46:00Z","timestamp":1792651560922,"version":"4.5.0"},"reference-count":131,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Applications of viral vectors have found an encouraging new beginning in gene therapy in recent years. Significant improvements in vector engineering, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors have been employed for the treatment of various diseases such as metabolic, cardiovascular, muscular, hematologic, ophthalmologic, and infectious diseases and different types of cancer. Recent development in the area of immunotherapy has provided both preventive and therapeutic approaches. Furthermore, gene silencing generating a reversible effect has become an interesting alternative, and is well-suited for delivery by viral vectors. A number of preclinical studies have demonstrated therapeutic and prophylactic efficacy in animal models and furthermore in clinical trials. Several viral vector-based drugs have also been globally approved.<\/jats:p>","DOI":"10.3390\/diseases6020042","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T04:34:03Z","timestamp":1526963643000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":446,"title":["Viral Vectors in Gene Therapy"],"prefix":"10.3390","volume":"6","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[{"name":"PanTherapeutics, CH1095 Lutry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMra032207","article-title":"Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency","volume":"350","author":"McCormack","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Garrigue","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0298-180","article-title":"Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity","volume":"18","author":"Schiedner","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/156652312800099599","article-title":"Biodistribution and safety assessment of bladder cancer specific oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice","volume":"12","author":"Wang","year":"2012","journal-title":"Curr. Gene Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1159\/000475909","article-title":"Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses","volume":"41","author":"Wei","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2741\/2872","article-title":"Cancer gene therapy using adeno-associated virus vectors","volume":"13","author":"Park","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno-associated virus serotypes: Impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J. Virol."},{"key":"ref_11","first-page":"611","article-title":"Adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes","volume":"90","author":"McClements","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/156652305774329285","article-title":"HSV-1 derived recombinant and amplicon vectors for gene transfer and gene therapy","volume":"5","author":"Epstein","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/13550280009006380","article-title":"A multi-mutant herpes simplex virus vector has minimal cytotoxic effects on the distribution of filamentous actin, alpha-actinin and a glutamate receptor in differentiated PC-12 cells","volume":"6","author":"Holmes","year":"2000","journal-title":"J. Neurovirol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-319-42934-2_2","article-title":"Retroviral vectors for cancer gene therapy","volume":"209","author":"Schambach","year":"2016","journal-title":"Recent Results Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0031-6997(24)01467-4","article-title":"Design of retroviral vectors and helper cells for gene therapy","volume":"52","author":"Hu","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1521-2254(200009\/10)2:5<308::AID-JGM131>3.0.CO;2-3","article-title":"Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy","volume":"2","author":"Vigna","year":"2000","journal-title":"J. Gen. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/fvl-2016-0028","article-title":"Self-replicating RNA viral vectors in vaccine development and gene therapy","volume":"11","author":"Lundstrom","year":"2016","journal-title":"Future Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/fvl-2017-0070","article-title":"Latest trends in cancer gene therapy applying viral vectors","volume":"12","author":"Lundstrom","year":"2017","journal-title":"Future Virol."},{"key":"ref_20","first-page":"635","article-title":"Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MHT-68\/H)","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2018). New frontiers in oncolytic viruses: Optimizing and selecting for virus strains with improved efficacy. Biol. Targets Ther., in press.","DOI":"10.2147\/BTT.S140114"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4684-5712-4_8","article-title":"An insight into poliovirus biology","volume":"257","author":"Crainic","year":"1989","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OV.S56322","article-title":"Applications of coxsackievirus A21 in oncology","volume":"3","author":"Bradley","year":"2014","journal-title":"Oncolytic Virother."},{"key":"ref_24","first-page":"161","article-title":"Poxviruses as vectors for cancer immunotherapy","volume":"6","author":"Kwak","year":"2003","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.cgt.7700549","article-title":"Development of a replication-selective oncolytic proxvirus for the treatment of human cancers","volume":"9","author":"Zeh","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.cgt.7700538","article-title":"Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors","volume":"9","author":"Mastrangelo","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s11262-017-1488-1","article-title":"Oncolytic viruses: Adenoviruses","volume":"53","author":"Niemann","year":"2017","journal-title":"Virus Genes"},{"key":"ref_28","first-page":"3599","article-title":"A tumor-targeting adenovirus with high gene-transduction efficiency for primary pancreatic cancer and ascites cells","volume":"37","author":"Nagasato","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/cam4.1185","article-title":"Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors","volume":"6","author":"Yamamoto","year":"2017","journal-title":"Cancer Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Emdad, L., Das, S.K., Wang, X.Y., Sarkar, D., and Fisher, P.B. (2017). Cancer Terminator Viruses (CVT): A better solution for viral-based therapy of cancer. J. Cell. Physiol.","DOI":"10.1002\/jcp.26421"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1089\/hum.2017.140","article-title":"Recent advances in preclinical developments using adenovirus hybrid vectors","volume":"28","author":"Zhang","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"89391","DOI":"10.18632\/oncotarget.20810","article-title":"Hitting the nail on the head: Combining oncolytic adenovirus-mediated virotherapy and immodulation for the treatment of glioma","volume":"8","author":"Panek","year":"2017","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","article-title":"Preclinical safety studies of Enadenotucirev, a chimeric group B human-specific oncolytic virus","volume":"5","author":"Illingworth","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_34","first-page":"153","article-title":"Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome","volume":"24","author":"Sinnett","year":"2017","journal-title":"Discov. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pfister, E., Dinardo, N., Mondo, E., Borel, F., Conroy, F., Fraser, C., Gernoux, G., Han, X., Hu, D., and Johnson, E. (2017). Artificial miRNAs reduce human mutant Huntingtin throughout the striatum in a transgenic sheep model of Huntington\u2019s disease. Hum. Gene Ther.","DOI":"10.1089\/hum.2017.199"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/humc.2017.067","article-title":"A preclinical study in Rhesus macaques for cystic fibrosis to assess gene transfer and transduction by AAV1 and AAV5 with a dual-luciferase reporter system","volume":"28","author":"Guggino","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/21678707.2016.1124039","article-title":"Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy","volume":"4","author":"Yue","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kodippili, K., Hakim, C.H., Pan, X., Yang, H.T., Yue, Y., Zhang, Y., Shin, J.H., Yang, N.N., and Duan, D. (2017). Dual AAV gene therapy for Duchenne muscular dystrophy with a 7-kb Mini-Dystrophin gene in the canine model. Hum. Gene Ther.","DOI":"10.1089\/hum.2017.095"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1089\/hum.2016.128","article-title":"Characterization of adeno-associated viral vector-mediated human Factor VIII gene therapy in hemophilia A mice","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mcn.2016.01.006","article-title":"Viral vector mediated continuous expression of interleukin-10 in DRG alleviates pain in type 1 diabetic animals","volume":"72","author":"Thankur","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/156652321305131212123237","article-title":"Targeted delivery of growth factors by HSV-mediated gene transfer for peripheral neuropathy","volume":"13","author":"Chattopadhyay","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fonc.2017.00149","article-title":"Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials","volume":"7","author":"Eissa","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2016.15","article-title":"Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models","volume":"23","author":"Yang","year":"2016","journal-title":"Gene Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/14712598.5.9.1175","article-title":"Gene therapy for severe combined immunodeficiences","volume":"5","author":"Gaspar","year":"2005","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_45","first-page":"111","article-title":"Novel immunotherapeutic approaches in targeting dendritic cells with virus vectors","volume":"20","author":"Fraefel","year":"2015","journal-title":"Discov. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2016.03.054","article-title":"Highly efficient gene transfer using a retroviral vector into murine T cells for preclinical chimeric antigen receptor-expressing T cell therapy","volume":"473","author":"Kusabuka","year":"2016","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/hum.2014.100","article-title":"Intravenous administration of retroviral replicating vector, Toca 511, demonstrates efficacy in orthotopic immune-competent mouse glioma model","volume":"26","author":"Huang","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/humc.2013.019","article-title":"From bench to bedside: Preclinical evaluation of a self-activating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease","volume":"24","author":"Stein","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2016.87","article-title":"Safe and efficient gene therapy of pyruvate kinase deficiency","volume":"24","author":"Calabria","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/hgtb.2013.016","article-title":"Lentiviral vector-mediated RNA silencing in the central nervous system","volume":"25","author":"Hutson","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","article-title":"Silencing of human \u03b1-synuclein in vitro and in rat brain using lentiviral-mediated RNAi","volume":"198","author":"Sapru","year":"2006","journal-title":"Exp. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jgm.1555","article-title":"Knockdown of GAD87 protein levels normalizes neuronal activity in a rat model of Parkinson\u2019s disease","volume":"13","author":"Horvath","year":"2011","journal-title":"J. Gene Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nn1531","article-title":"Targeting BACE1 with siRNAs ameliorates Alzheimer\u2019s disease neuropathology in a transgenic model","volume":"8","author":"Singer","year":"2005","journal-title":"Nat. Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1523\/JNEUROSCI.3637-10.2010","article-title":"Silencing of CDK5 reduces neurofibrillary tangles in Alzheimer\u2019s mice","volume":"30","author":"Piedrahita","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ringpis, G.E., Shimizu, S., Arokium, H., Camba-Col\u00f3n, J., Carroll, M.V., Cortado, R., Xie, Y., Kim, P.Y., Sahakyan, A., and Lowe, E.L. (2012). Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem\/progenitor cells in humanized BLT mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0053492"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16007","DOI":"10.1038\/mtm.2016.7","article-title":"Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS","volume":"3","author":"Peterson","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2017). Oncolytic alphaviruses in cancer Immunotherapy. Vaccines, 5.","DOI":"10.3390\/vaccines5020009"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/ijc.23646","article-title":"Replication competent Semliki Forest virus prolongs survival in experimental lung cancer","volume":"123","author":"Ketola","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2990.2010.01110.x","article-title":"Semliki Forest virus-mediated gene therapy of the RG2 rat glioma","volume":"36","author":"Roche","year":"2010","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1128\/JVI.01940-12","article-title":"Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting","volume":"87","author":"Ylosmaki","year":"2013","journal-title":"J. Virol"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","article-title":"Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers","volume":"111","author":"Lin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2008.169","article-title":"A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy","volume":"16","author":"Smeenk","year":"2009","journal-title":"Gene Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-006-0042-3","article-title":"Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector","volume":"28","author":"Clarke","year":"2006","journal-title":"Springer Semin. Immunopathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency","volume":"74","author":"Muik","year":"2014","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/humc.2016.061","article-title":"Safety studies in tumor and non-tumor-bearing mice in support of clinical trials using oncolytic VSV-IFN\u03b2-NIS","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/humc.2013.165","article-title":"Safety studies on intravenous administration of onclolytic recombinant vesicular stomatitis virus in purpose-bread beagle dogs","volume":"24","author":"LeBlanc","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1099\/vir.0.046672-0","article-title":"Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer","volume":"93","author":"Hastie","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/cgt.2012.47","article-title":"Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy","volume":"19","author":"Reddi","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2013.05.004","article-title":"Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase","volume":"130","author":"Hartkopf","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/gt.2013.28","article-title":"An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis","volume":"20","author":"Lampe","year":"2013","journal-title":"Gene Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2012.136","article-title":"A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma","volume":"24","author":"Lange","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7785\/tcrt.2012.500414","article-title":"Recombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model","volume":"14","author":"Niu","year":"2015","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Chai, Z., Zhang, P., Fu, F., Zhang, X., Liu, Y., Hu, L., and Li, X. (2014). Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer. Virol. J., 11.","DOI":"10.1186\/1743-422X-11-84"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4161\/cbt.29686","article-title":"Genetically engineered Newcastle disease virus expressing interleukin-12 and TNF-related and apoptosis-inducing ligand for cancer therapy","volume":"15","author":"Bai","year":"2014","journal-title":"Cancer Ther. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2017.02.042","article-title":"Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy","volume":"802","author":"Wu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/gt.2011.201","article-title":"Coxsackievirus B3 used as a gene therapy vector to express functional FGF2","volume":"19","author":"Kim","year":"2012","journal-title":"Gene Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1158\/1078-0432.CCR-0690-3","article-title":"Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21","volume":"10","author":"Shafren","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-008-9899-2","article-title":"Systemic targeting of metastatic human breast xenografts by Coxsackievirus A21","volume":"113","author":"Skelding","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s10637-010-9614-0","article-title":"Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride","volume":"30","author":"Skelding","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/pros.20741","article-title":"Potent oncolytic activity of human enteroviruses against human prostate cancer","volume":"68","author":"Berry","year":"2008","journal-title":"Prostate"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2217\/imt.15.90","article-title":"Vaccinia virus, a promising new therapeutic agent for pancreatic cancer","volume":"7","author":"Zhang","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/14712598.7.4.543","article-title":"PANVAC-VF: Poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma","volume":"7","author":"Madan","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.surg.2015.03.044","article-title":"Oncolytic gene therapy with recombinant vaccinia virus strain GLV-2b372 efficiently kills hepatocellular carcinoma","volume":"158","author":"Ady","year":"2015","journal-title":"Surgery"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/gt.2016.5","article-title":"Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer","volume":"23","author":"Mansfield","year":"2016","journal-title":"Gene Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"638","DOI":"10.15252\/emmm.201607296","article-title":"Deletion of F4L (ribonucleotide recductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models","volume":"9","author":"Potts","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2017.08.003","article-title":"Cowpox virus: A new and armed oncolytic poxvirus","volume":"7","author":"Ricordel","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Salazar","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Chapin, J.C., and Monahan, P.E. (2017). Gene therapy for hemophilia. BioDrugs.","DOI":"10.1007\/s40259-017-0255-0"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/hae.13011","article-title":"State of the art: Gene therapy of haemophilia","volume":"22","author":"Spencer","year":"2016","journal-title":"Haemophilia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/jgm.2769","article-title":"Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells","volume":"16","author":"Dodd","year":"2014","journal-title":"J. Gene Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"341ra75","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase I trial of vocimagine amiroretrorepvec and 5-fluorocytosine for recurrent high-grade glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_92","unstructured":"(2018, May 14). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02414165\/."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","article-title":"Phase I study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers","volume":"24","author":"Guo","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14760584.5.1.9","article-title":"Development of the PANVAC-VF vaccine for pancreatic cancer","volume":"5","author":"Petrulio","year":"2006","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_95","unstructured":"(2018, April 27). Therion Reports Results of Phase 3 panvac-vf Trial and Announces Plans for Company Sale. PR Newswire 28 June. Available online: www.prnewswire.com."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.4161\/hv.36241","article-title":"Human vaccines & immunotherapeutics: News","volume":"10","author":"Riedmann","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2016.031","article-title":"Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent\/progressive glioblastoma multiforme, anaplastic astocytoma or gliosarcoma","volume":"27","author":"Patel","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase 1b trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM","volume":"17","author":"Markert","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase I trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Markert","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/humc.2017.002","article-title":"Rationale and design of a phase I clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or recurrent malignant supratentorial brain tumors","volume":"28","author":"Waters","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.vaccine.2012.11.096","article-title":"A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer","volume":"31","author":"Slovin","year":"2013","journal-title":"Vaccine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1038\/sj.gt.3302620","article-title":"Biology and applications of alphaviruses in gene therapy","volume":"12","author":"Lundstrom","year":"2005","journal-title":"Gene Ther."},{"key":"ref_103","first-page":"49","article-title":"Therapeutic potential of oncolytic Newcastle disease virus: A critical review","volume":"4","author":"Tayeb","year":"2015","journal-title":"Oncolytic Virother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00262-004-0602-0","article-title":"Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory","volume":"54","author":"Schirrmacher","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1610-0387.2003.02014.x","article-title":"Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease","volume":"1","author":"Voit","year":"2003","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3748\/wjg.v9.i3.495","article-title":"Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract","volume":"9","author":"Liang","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.3390\/v7082816","article-title":"CCR5 targeted cell therapy for HIV and prevention of viral escape","volume":"7","author":"Bodor","year":"2015","journal-title":"Viruses"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1073\/pnas.232688199","article-title":"Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5","volume":"100","author":"Qin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","unstructured":"(2017, May 14). Available online: http:\/\/fdaaa.trialstracker.net\/trial\/ NCT01734850\/."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"P341","DOI":"10.1186\/2051-1426-3-S2-P341","article-title":"Phase I\/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients","volume":"3","author":"Pandha","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"P343","DOI":"10.1186\/2051-1426-3-S2-P343","article-title":"Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment","volume":"3","author":"Andtbacka","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"CT026","DOI":"10.1158\/1538-7445.AM2017-CT026","article-title":"Abstract CT026: Phase 1b study of intratumoral coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial","volume":"77","author":"Silk","year":"2017","journal-title":"Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","article-title":"Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis","volume":"72","author":"Alton","year":"2017","journal-title":"Thorax"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1874467210801010013","article-title":"Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications","volume":"1","author":"Pikkarainen","year":"2008","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/gt.2008.72","article-title":"Gene therapy progress and prospects cancer: Oncolytic viruses","volume":"15","author":"Liu","year":"2008","journal-title":"Gene Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_120","unstructured":"(2017, April 21). Available online: https:\/\/european-biotechnology.com\/up-to-date\/latest-news\/news\/uniqure-withdraws-eur1m-drug-glybera-from-market.html."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10637-009-9279-8","article-title":"REO-001: Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients in advanced solid tumors","volume":"28","author":"Gollamudi","year":"2010","journal-title":"Investig. New Drugs"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1142\/S1568558610000185","article-title":"Clinical development of a third-generation HSV-1 (G47\u0394) for malignant glioma","volume":"5","author":"Ino","year":"2010","journal-title":"Gene Ther. Regul."},{"key":"ref_125","first-page":"313","article-title":"Pressing diseases that represent promising targets for gene therapy","volume":"24","author":"Beitelshees","year":"2017","journal-title":"Discov. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/mt.2016.55","article-title":"Evaluating the safety of retroviral vectors based on insertional oncogene activation and blocked differentiation in cultured thymocytes","volume":"24","author":"Zhou","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2017.098","article-title":"Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to Good Manufacturing Practice","volume":"29","author":"Gandara","year":"2018","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1021074613196","article-title":"HIV-1 vector systems","volume":"26","author":"Srinivasakumar","year":"2001","journal-title":"Somat. Cell Mol. Genet."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.omtm.2017.03.009","article-title":"Toward personalized gene therapy: Characterizing the host genetic control of lentiviral-vector-mediated hepatic gene delivery","volume":"5","author":"Suwanmanee","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/2326-6066.CIR-17-0434","article-title":"Rapid construction of antitumor T-cell receptor vectors from frozen tumors for engineered T-cell therapy","volume":"6","author":"Tsuji","year":"2018","journal-title":"Cancer Immunol. Res."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/6\/2\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:05:15Z","timestamp":1760195115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/6\/2\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":131,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["diseases6020042"],"URL":"https:\/\/doi.org\/10.3390\/diseases6020042","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]}}}